Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-α

被引：0
|
作者：
De Ridder, K. [1 ]
Locy, H. [1 ]
Piccioni, E. [1 ]
Zuazo, M. Ibarra [2 ]
Awad, R. M. [1 ]
Verhulst, S. [3 ,4 ]
van Bulck, M. [5 ]
De Vlaeminck, Y. [1 ]
Lecocq, Q. [1 ]
Reijmen, E. [1 ]
De Mey, W. [1 ]
De Beck, L.
Ertveldt, T. [1 ]
Pintelon, I. [6 ]
Timmermans, J-P. [6 ]
Escors, D. [2 ]
Keyaerts, M. [7 ]
Breckpot, K. [1 ]
Goyvaerts, C. [1 ]
机构：
[1] Vrije Univ Brussel, Fac Med & Pharm, Dept Biomed Sci, Lab Mol & Cellular Therapy, Brussels, Belgium
[2] Navarrabiomed UPNA IdISNA, Immunomodulat Grp, Pamplona, Spain
[3] Dept Biomed Sci, Brussels, Belgium
[4] Liver Cell Biol Res Grp, Jette, Belgium
[5] Vrije Univ Brussel, Dept Biomed Sci, Lab Mol & Med Oncol, Jette, Belgium
[6] Univ Antwerp, Antwerp Ctr Adv Microscopy ACAM, Lab Cell Biol & Histol, Antwerp, Belgium
[7] Vrije Univ Brussel, Fac Med & Pharm, Invivo Cellular & Mol Imaging Lab, Jette, Belgium
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.200
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
168P
引用
收藏
页码：S109 / S109
页数：1
相关论文
共 50 条
  • [41] Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
    Yuan, Meng
    Zhai, Yirui
    Men, Yu
    Zhao, Maoyuan
    Sun, Xin
    Ma, Zeliang
    Bao, Yongxing
    Yang, Xu
    Sun, Shuang
    Liu, Yunsong
    Zhang, Wanting
    Hui, Zhouguang
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2022, 2022
  • [42] Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy
    Schaberg, Kurt B.
    Novoa, Roberto A.
    Wakelee, Heather A.
    Kim, Jinah
    Cheung, Christine
    Srinivas, Sandhya
    Kwong, Bernice Y.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2016, 43 (04) : 339 - 346
  • [43] Integrative Modeling of Tumor Burden and Metastatic Pattern for Second-Line anti-PD-L1 Therapy of NoneSmall Cell Lung Cancer
    Ma, S.
    Tang, X.
    Bai, X.
    Dong, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S574 - S575
  • [44] Basic study of immunoradiation therapy using anti-PD-L1 antibody
    Hara, Takamitsu
    Sato, Hiroo
    Suzuki, Yoshiyuki
    Ohno, Tatsuya
    Okazaki, Atsushi
    CANCER SCIENCE, 2022, 113 : 613 - 613
  • [45] Anti-PD-L1 therapy-associated hypophysitis and limbic encephalitis
    Arthur Matthys
    Sophie Demeret
    Delphine Leclercq
    Lucas Di Meglio
    Intensive Care Medicine, 2022, 48 : 1807 - 1808
  • [46] In vivo efficacy of intraperitoneal anti-PD-L1 therapy in ovarian cancer
    Grabosch, Shannon
    Mony, Jyothi T.
    Zhang, Lixin
    Ma, Tianzhou
    Tirodkar, Tejas
    Brozick, Joan
    Tseng, George
    Elishaev, Esther
    Edwards, Robert P.
    Huang, Xin
    Vlad, Anda M.
    CANCER RESEARCH, 2015, 75
  • [47] Anti-PD-L1 therapy-associated hypophysitis and limbic encephalitis
    Matthys, Arthur
    Demeret, Sophie
    Leclercq, Delphine
    Di Meglio, Lucas
    INTENSIVE CARE MEDICINE, 2022, 48 (12) : 1807 - 1808
  • [48] Epitope characterization of an anti-PD-L1 antibody using orthogonal approaches
    Hao, Gang
    Wesolowski, John S.
    Jiang, Xuliang
    Lauder, Scott
    Sood, Vanita D.
    JOURNAL OF MOLECULAR RECOGNITION, 2015, 28 (04) : 269 - 276
  • [49] Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
    Banna, Giuseppe Luigi
    Cantale, Ornella
    Bersanelli, Melissa
    Del Re, Marzia
    Friedlaender, Alex
    Cortellini, Alessio
    Addeo, Alfredo
    ONCOLOGY REVIEWS, 2020, 14 (02) : 135 - 143
  • [50] A Mismatch Repair-Deficient Hepatoid Adenocarcinoma of the Lung Responding to Anti-PD-L1 Durvalumab Therapy Despite no PD-L1 Expression
    Basse, Victor
    Schick, Ulrike
    Gueguen, Paul
    Le Marechal, Cedric
    Quintin-Roue, Isabelle
    Descourt, Renaud
    Simon, Helene
    Uguen, Arnaud
    Quere, Gilles
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (07) : E120 - E122
12345